In a report released today, David Buck from B.Riley FBR reiterated a Buy rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $31. The company’s shares closed on Friday at $23.90, close to its 52-week high of $25.63.
According to TipRanks.com, Buck is a 4-star analyst with an average return of 14.7% and a 71.4% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Amag Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $23.60.
See today’s analyst top recommended stocks >>
Based on Amag Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.08 million. In comparison, last year the company had a GAAP net loss of $14.07 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.
